

**RE: Freedom of Information Request 201718 / 053 – MS Drugs**

Your Query	Date of Request	May 2017
<p data-bbox="81 477 1481 544">In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.</p> <p data-bbox="81 577 1481 611">Please provide the number of patients by treatment for the following disease modifying drugs:</p> <ul data-bbox="140 656 614 1216" style="list-style-type: none"><li>• Aubagio (teriflunomide)</li><li>• Avonex (interferon beta-1a)</li><li>• Betaferon (interferon beta-1b)</li><li>• Copaxone (glatiramer acetate)</li><li>• Extavia (beta interferon-1b)</li><li>• Gilenya (fingolimod)</li><li>• Lemtrada (alemtuzumab)</li><li>• Rebif (beta interferon-1a)</li><li>• Tecfidera (dimethyl fumarate)</li><li>• Tysabri (natalizumab)</li><li>• Ampyra (Fampyra)</li><li>• Peginterferon beta-1a (Plegridy)</li><li>• Daclizumab (Zinbryta)</li><li>• Ocrevus (Ocrelizumab)</li><li>• Others</li></ul>		
Response		
<p data-bbox="81 1361 1481 1462">The small size of the Orkney population and the small sample size result in the numbers involved being less than five meaning that the data is potentially patient-identifiable. It is therefore exempt under Section 38(1)(b) of the Freedom of Information (Scotland) Act 2002.</p>		